Ieq Capital LLC lessened its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 3.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 411,276 shares of the biopharmaceutical company’s stock after selling 13,406 shares during the quarter. Ieq Capital LLC owned approximately 0.20% of Incyte worth $49,908,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the business. Trails Edge Capital Partners LP acquired a new stake in shares of Incyte in the 2nd quarter valued at approximately $17,570,800. Tidal Investments LLC grew its holdings in Incyte by 33.4% during the second quarter. Tidal Investments LLC now owns 102,834 shares of the biopharmaceutical company’s stock worth $11,657,000 after acquiring an additional 25,768 shares during the period. BlackRock Inc. acquired a new stake in Incyte in the second quarter valued at $2,044,189,000. State of Wyoming acquired a new stake in Incyte in the second quarter valued at $4,027,000. Finally, Insight Wealth Strategies LLC acquired a new stake in Incyte in the second quarter valued at $7,076,000. 96.97% of the stock is currently owned by hedge funds and other institutional investors.
Incyte Stock Performance
Incyte stock opened at $117.36 on Thursday. Incyte Corporation has a fifty-two week low of $89.25 and a fifty-two week high of $132.60. The firm has a market capitalization of $23.92 billion, a price-to-earnings ratio of 62.93, a price-to-earnings-growth ratio of 4.24 and a beta of 0.78. The stock’s fifty day moving average is $118.78 and its two-hundred day moving average is $109.23.
Incyte (NASDAQ:INCY – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.93) by $0.33. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The business had revenue of $1.56 billion during the quarter, compared to the consensus estimate of $1.46 billion. During the same quarter in the previous year, the company posted $2.26 EPS. The business’s revenue was up 14.0% on a year-over-year basis. As a group, sell-side analysts forecast that Incyte Corporation will post 2.29 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research firms have recently weighed in on INCY. JPMorgan Chase & Co. upped their price target on shares of Incyte from $120.00 to $123.00 and gave the stock a “neutral” rating in a research note on Monday, September 28th. Piper Sandler raised their price objective on shares of Incyte from $110.00 to $130.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Wall Street Zen downgraded shares of Incyte from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Stifel Nicolaus upped their target price on shares of Incyte from $145.00 to $157.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Incyte in a research report on Tuesday, October 27th. Eleven research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $133.86.
Read Our Latest Analysis on Incyte
Insider Buying and Selling at Incyte
In other Incyte news, EVP Lee Heeson sold 10,694 shares of the firm’s stock in a transaction dated Friday, November 13th. The shares were sold at an average price of $120.82, for a total transaction of $1,292,049.08. Following the completion of the transaction, the executive vice president directly owned 26,884 shares in the company, valued at approximately $3,248,124.88. This trade represents a 28.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Tray sold 610 shares of Incyte stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total transaction of $72,565.60. Following the transaction, the insider owned 21,126 shares of the company’s stock, valued at approximately $2,513,148.96. The trade was a 2.81% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 254,139 shares of company stock valued at $30,098,844 in the last quarter. Insiders own 16.20% of the company’s stock.
About Incyte
Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.
Featured Stories
- Five stocks we like better than Incyte
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
- Apple’s Next Margin Defense Could Be Hiding in Your Wallet
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY – Free Report).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.
